| Citation: |
ZHOU Li, CHI Zhihong, CUI Chuanliang, SHENG Xi'nan, SI Lu, TANG Bixia, MAO Lili, WANG Xuan, YAN Xieqiao, LIAN Bin, LI Siming, BAI Xue, GUO Jun. Efficacy and Safety of Paclitaxel, Ifosfamide and Cisplatin as First-line Treatment on Patients with Intermediate- or Poor-risk Advanced Testicular Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(6): 400-403. DOI: 10.3971/j.issn.1000-8578.2018.17.1417
|
To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively.
Patients with intermediate- or poor-risk testicular cancer in our center received TIP as the first-line treatment. Objective response rate, 2-year progression free survival(PFS) and overall survival(OS) were evaluated.
The mean treatment of 20 patients was 4.25cycles. Six patients achieved CR(30%), seven patients had partial response(35%) and overall response rate was 65%. The median follow-up time was 25 months. Three patients died of tumor progression. Hematologic toxicity was most common(95%), with 30% of grade 3-4 neutropenia. Estimated 2-year PFS was 72.9% and OS was 89.1%.
Paclitaxel, ifosfamide and cisplatin(TIP) are safe and effective as the first-line treatment on patients with intermediate- or poor-risk testicular cancer. Compared with previous studies, 2-year PFS and OS have been improved. Adverse effect could be controlled. Further researches are still needed.
| [1] |
Hanna NH, Einhorn LH. Testicular cancer--discoveries and updates[J]. N Engl J Med, 2014, 371(21): 2005-16. doi: 10.1056/NEJMra1407550
|
| [2] |
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group[J]. J Clin Oncol, 1997, 15(2): 594-603. doi: 10.1200/JCO.1997.15.2.594
|
| [3] |
Kurobe M, Kawai K, Oikawa T, et al. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor[J]. J Cancer Res Clin Oncol, 2015, 141(1): 127-33. doi: 10.1007/s00432-014-1760-x
|
| [4] |
Daugaard G, Skoneczna I, Aass N, et al. A randomized phase Ⅲ study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)[J]. Ann Oncol, 2011, 22(5): 1054-61. doi: 10.1093/annonc/mdq575
|
| [5] |
de Wit R, Skoneczna I, Daugaard G, et al. Randomized Phase Ⅲ Study Comparing Paclitaxel-Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983[J]. J Clin Oncol, 2012, 30(8): 792-9. doi: 10.1200/JCO.2011.37.0171
|
| [6] |
Huddart RA, Gabe R, Cafferty FH, et al. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)[J]. Eur Urol, 2015, 67(3): 534-43. doi: 10.1016/j.eururo.2014.06.034
|
| [7] |
Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial[J]. Cancer, 2003, 97(8): 1869-75. doi: 10.1002/cncr.11271
|
| [8] |
Motzer RJ, Nichols CJ, Margolin KA, et al. Phase Ⅲ randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors[J]. J Clin Oncol, 2007, 25(3): 247-56. doi: 10.1200/JCO.2005.05.4528
|
| [9] |
Feldman DR, Hu J, Dorff TB, et al. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors[J]. J Clin Oncol, 2016, 34(21): 2478-83. doi: 10.1200/JCO.2016.66.7899
|
| [10] |
Nishikawa M, Miyake H, Muramaki M, et al. Efficacy and tolerability of TIP (paclitaxel, ifosfamide and cisplatin) incorporated into induction chemotherapy for patients with intermediate- or poor-risk metastatic germ cell tumors[J]. Med Oncol, 2014, 31(12): 296. doi: 10.1007/s12032-014-0296-x
|
| [11] |
Ko JJ, Bernard B, Tran B, et al. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy[J]. J Clin Oncol, 2016, 34(7): 714-20. doi: 10.1200/JCO.2015.64.7909
|
| [12] |
Litchfield K, Levy M, Orlando G, et al. Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor[J]. Nat Genet, 2017, 49(7): 1133-40. doi: 10.1038/ng.3896
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: